Voluntary price reduction of generic products in the NSAID ‘celecoxib’ war

Published: 2015-06-05 13:46:49

Updated: 2015-06-05 13:46:49

As the patent of the selective COX-2 inhibition anti-inflammatory drug ‘Celebrex(generic name: celecoxib)’ will be expired on the coming 11^th of June, approximately 100 generics are expected to be poured out.

Since its launch in 2000, the drug, recoding KRW 56.5 billion health insurance fees last year, has accounted for 15% of the entire KRW 400 billion non-steroidal anti-inflammatory drug (NS...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.

Voluntary price reduction of generic products in the NSAID ‘celecoxib’ war

As the patent of the selective COX-2 inhibition anti-inflammatory drug ‘Celebrex(generic name: celecoxib)’ will be expired on the coming 11th of June, approximately 100 generics are expected to be poured out.

Fees

As the patent of the selective COX-2 inhibition anti-inflammatory drug ‘Celebrex(generic name: celecoxib)’ will be expired on the coming 11^th of June, approximately 100 generics are expected to be poured out.